Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H16ClN3O2 |
| Molecular Weight | 233.695 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClCCN(N=O)C(=O)NC1CCCCC1
InChI
InChIKey=GQYIWUVLTXOXAJ-UHFFFAOYSA-N
InChI=1S/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14)
Lomustine is used in the treatment of certain neoplastic diseases. Although it is generally agreed that lomustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. Common adverse reactions include delayed myelosupression, nausea, vomiting, stomatitis, and alopecia.
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. | 2001 |
|
| [Post-operative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of German prospective randomised trial HIT'91]. | 2001 Apr |
|
| Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas. | 2001 Apr |
|
| Chemotherapy for the treatment of oligodendroglial tumors. | 2001 Aug |
|
| Melanoma-associated retinopathy: does autoimmunity prolong survival? | 2001 Aug |
|
| Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide. | 2001 Feb |
|
| Adult medulloblastoma: multiagent chemotherapy. | 2001 Jan |
|
| Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. | 2001 Jan 15 |
|
| Spin labelled nitrosoureas and triazenes and their non-labelled clinically used analogues--a comparative study on their physicochemical properties and antimelanomic effects. | 2001 Jan 16 |
|
| Protection of hematopoietic cells from O(6)-alkylation damage by O(6)-methylguanine DNA methyltransferase gene transfer: studies with different O(6)-alkylating agents and retroviral backbones. | 2001 Jul |
|
| PCV chemotherapy for recurrent glioblastoma multiforme. | 2001 Jun 26 |
|
| [Therapeutic effect on glioblastoma of chemotherapy on the basis of brain irradiation]. | 2001 Mar |
|
| Death receptor-independent cytochrome c release and caspase activation mediate thymidine kinase plus ganciclovir-mediated cytotoxicity in LN-18 and LN-229 human malignant glioma cells. | 2001 Mar |
|
| Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. | 2001 May 1 |
|
| Lipid association improves the therapeutic index of lomustine [1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea] to suppress 36B-10 tumor growth in rats. | 2001 May 1 |
|
| The effectiveness of the O(6)-alkylguanine-DNA alkyltransferase encoded by the ogt(ST) gene from S. typhimurium in protection against alkylating drugs, resistance to O(6)-benzylguanine and sensitisation to dibromoalkane genotoxicity. | 2001 Oct 18 |
|
| Nitric oxide and free stable nitroxyl radicals in the mechanism of biological action of the spin-labeled compounds. | 2001 Sep |
|
| 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. | 2002 Apr |
|
| Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil. | 2002 Aug |
|
| Coeliac disease following high-dose chemotherapy. | 2002 Dec |
|
| Recurrent malignant glioma in adults. | 2002 Dec |
|
| Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. | 2002 Dec 1 |
|
| An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. | 2002 Dec 15 |
|
| High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. | 2002 Feb 1 |
|
| Long-term follow-up in managing anaplastic astrocytoma by multimodality approach with surgery followed by postoperative radiotherapy and PCV-chemotherapy: phase II trial. | 2002 Jun |
|
| Study of three hepatobiliary agents in experimental animals. | 2002 Mar-Apr |
|
| NO-mediated chemoresistance in C6 glioma cells. | 2002 May |
|
| [Chemo-radiotherapy for malignant brain tumors]. | 2002 May |
|
| Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. | 2002 May 1 |
|
| Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. | 2002 Sep-Oct |
|
| Low-dose continuous chemotherapy for metastatic melanoma: a phase II trial. | 2003 Apr |
|
| Recent developments in the molecular characterization and treatment of oligodendroglial tumors. | 2003 Apr |
|
| Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: case report and literature review. | 2003 Apr |
|
| Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. | 2003 Apr |
|
| Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. | 2003 Jul 15 |
|
| Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. | 2003 Jul 21 |
|
| Myeloid clonogenic assays for comparison of the in vitro toxicity of alkylating agents. | 2003 Jun |
|
| Survival improvement in patients with glioblastoma multiforme during the last 20 years in a single tertiary-care center. | 2003 Jun 24 |
|
| Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. | 2003 Mar |
|
| Interobserver variability in the radiological assessment of response to chemotherapy in glioma. | 2003 Mar 11 |
|
| Conformal irradiation for pure and mixed oligodendroglioma: the experience of Centre Leon Berard Lyon. | 2003 May 1 |
Sample Use Guides
Recommended dose in adult and pediatric patients is 130 mg/m2 orally every 6 weeks.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LIVERTOX |
566
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
||
|
NCI_THESAURUS |
C699
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
||
|
NDF-RT |
N0000000236
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
||
|
WHO-VATC |
QL01AD02
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
||
|
WHO-ATC |
L01AD02
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
||
|
NDF-RT |
N0000175558
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB08567MIG
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
PRIMARY | |||
|
13010-47-4
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
PRIMARY | |||
|
M6891
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
PRIMARY | Merck Index | ||
|
3950
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
PRIMARY | |||
|
13010-47-4
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
PRIMARY | |||
|
6466
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
PRIMARY | RxNorm | ||
|
13010-47-4
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
PRIMARY | |||
|
LOMUSTINE
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
PRIMARY | |||
|
D008130
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
PRIMARY | |||
|
7214
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
PRIMARY | |||
|
C617
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
PRIMARY | |||
|
DB01206
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
PRIMARY | |||
|
235-859-2
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
PRIMARY | |||
|
3184
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
PRIMARY | |||
|
CHEMBL514
Created by
admin on Tue Oct 22 00:33:23 UTC 2019 , Edited by admin on Tue Oct 22 00:33:23 UTC 2019
|
PRIMARY |
ACTIVE MOIETY
